Formerly | Alder Biopharmaceuticals |
---|---|
Type | Subsidiary |
Founded | 1 January 2004 |
Headquarters | , U.S. |
Parent | Lundbeck |
Website | https://www.lundbeck.com/us/about-us/lundbeck-in-the-us |
Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.
In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]
As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]
References
- ↑ "Alder BioPharmaceuticals stock flat after unexciting IPO". geekwire.com. 8 May 2014. Retrieved 24 August 2017.
- ↑ "Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma". Drug Development Technology. Kable. 2 February 2018. Retrieved 3 February 2018.
- ↑ "Alder Biopharmaceuticals Inc - Company Profile and News". Bloomberg.com. Retrieved 2019-05-21.
- ↑ Kilgore, Tomi (2019-09-16). "Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal". Market Watch. Retrieved 2019-10-21.
- ↑ staff, Seattle Times business (2019-09-16). "Alder BioPharma, Bothell developer of migraine-prevention drug, acquired for up to $2 billion". The Seattle Times. Retrieved 2020-06-18.
{{cite web}}
:|first=
has generic name (help) - ↑ Podsada, Janice (August 5, 2020). "Bay Area bio-tech firm to open production plant in Bothell". The Everett Herald. Retrieved February 19, 2022.